Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems

Journal Title: The AAPS Journal - Year 2005, Vol 7, Issue 4

Abstract

Despite its apparent easy accessibility, the eye is, in fact, well protected against the absorption of foreign materials, including therapeutic agents, by the eyelids, by the tearflow, and by the permeability barriers imposed by the cornea on one side and the blood-retinal barrier on the other. Most existing ophthalmic drugs were adapted from other therapeutic applications and were not specifically developed for the treatment of eye diseases; hence, they are not well suited to provide eye-specific effects without causing systemic side effects. A real breakthrough in the area of ophthalmic therapeutics can be achieved only by specifically designing new drugs for ophthalmic applications to incorporate the possibility of eye targeting into their chemical structure. Possibilities provided along these lines by designing chemical delivery systems (CDSs) and soft drugs within the framework of retrometabolic drug design are reviewed here. Both are general concept applicable in almost any therapeutic area. This review will concentrate on \-adrenergic agonists and anti-inflammatory corticosteroids, where clinical results obtained with new chemical entities, such as betaxoxime, adaprolol, loteprednol etabonate, and etiprednol dicloacetate, exist to support the advantages of such metabolism-focused, ophthalmic-specific drug design approaches.

Authors and Affiliations

Nicholas Bodor, Peter Buchwald

Keywords

Related Articles

Analyzing Subvisible Particles in Protein Drug Products: a Comparison of Dynamic Light Scattering (DLS) and Resonant Mass Measurement (RMM)

Aggregation is common in protein drug manufacture, and while the effects of protein particulates are under investigation, many techniques applicable for their characterization have been recently developed. Among the meth...

Solvation and hydration characteristics of ibuprofen and acetylsalicylic acid

Ibuprofen and acetylsalicylic acid were studied by thermoanalytical methods: sublimation calorimetry, solution calorimetry, and with respect to solubility. Upon measuring the temperature dependences of the saturated vapo...

Immunogenicity of Subcutaneously Administered Therapeutic Proteins—a Mechanistic Perspective

The administration of therapeutic proteins via the subcutaneous route (sc) is desired for compliance and convenience, but could be challenging due to perceived immunogenic potential or unwanted immune responses. There ar...

Understanding the Effect of API Properties on Bioavailability Through Absorption Modeling

This article inadvertently failed to include two of the theme issue guest editors. The complete listing of the guest editors is shown in this erratum.

A Physiologically Based Pharmacokinetic Model of Mitoxantrone in Mice and Scale-up to Humans: a Semi-Mechanistic Model Incorporating DNA and Protein Binding

We conducted a pharmacokinetic (PK) study of mitoxantrone (Novantrone®), a clinically well-established anticancer agent, in mice and developed a mechanism-based PBPK (physiologically based pharmacokinetic) model...

Download PDF file
  • EP ID EP681902
  • DOI  10.1208/aapsj070479
  • Views 72
  • Downloads 0

How To Cite

Nicholas Bodor, Peter Buchwald (2005). Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems. The AAPS Journal, 7(4), -. https://europub.co.uk/articles/-A-681902